Maze Therapeutics, Inc. (MAZE)
| Market Cap | 1.94B +40.9% |
| Revenue (ttm) | 20.00M |
| Net Income | -151.47M |
| EPS | -2.67 |
| Shares Out | 54.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,136,209 |
| Open | 34.44 |
| Previous Close | 34.91 |
| Day's Range | 34.21 - 35.73 |
| 52-Week Range | 21.95 - 53.65 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 62.62 (+76.64%) |
| Earnings Date | Nov 9, 2026 |
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also deve... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MAZE stock is "Strong Buy." The 12-month stock price target is $62.62, which is an increase of 76.64% from the latest price.
News
Maze Therapeutics price target lowered to $51 from $53 at JPMorgan
JPMorgan analyst Anupam Rama lowered the firm’s price target on Maze Therapeutics (MAZE) to $51 from $53 and keeps an Overweight rating on the shares.
Maze Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
HORIZON enrolled more than 50 patients, exceeding its target, with 2027 APOL1 data expected. MZE782’s placebo-controlled PKU study is underway, and a CKD proof-of-concept study is planned for 2027.
Maze Therapeutics reports Q3 EPS (79c), consensus (75c)
Reports Q3 net loss $48.0M vs. $30.1M last year. Cash, cash equivalents and marketable securities were $477.0M as of September 30, which the company expects will fund operations into 2029.
Maze Therapeutics completes enrollment in Phase 2 HORIZON trial
Maze Therapeutics (MAZE) announced that enrollment is complete in the Phase 2 HORIZON trial evaluating MZE829 in more than 50 patients with APOL1-mediated kidney disease across three cohorts, exceedin...
Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027
Maze Therapeutics Earnings release: Q3 2026
Maze Therapeutics released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Maze Therapeutics Quarterly report: Q3 2026
Maze Therapeutics has published its Q3 2026 quarterly earnings report on November 9, 2026.
Maze Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pati...
Maze Therapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $75 price target The company’s lead asset MZE829 is an oral small molecule APOL1 inhibitor for APOL1 mediated…
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research support...
Maze Therapeutics initiated with a Buy at Citi
Citi initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $50 price target The firm sees the company’s APOL1-mediated kidney disease assets driving upside over the medium term.
Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.
Maze Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Three clinical programs are advancing, with key HORIZON phase II data for AMKD expected soon and a pivotal trial planned. Initial results show strong efficacy across patient subgroups, and biomarker strategies are being explored. The PKU program is also progressing with promising early data.
Maze Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
MZE829 interim HORIZON results showed UACR reductions across AMKD subtypes; final data are expected by year-end 2026 or early 2027, ahead of a planned H1 2027 pivotal start. MZE782 Phase II studies target PKU and CKD, with PKU data guided for 2027.
Maze Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Three clinical programs are advancing, with MZE829 showing promising phase II results in AMKD and broad potential across patient subgroups. Key data readouts and trial initiations are expected over the next two years, supported by strong financial resources and ongoing industry collaboration.
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pat...
Maze Therapeutics Announces Appointments to Its Board of Directors
Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze's Board of Directors, adding to the Company's deep bench of clinical and industry experience
Maze Therapeutics reports Q2 EPS (76c), consensus (70c)
“The second quarter was marked by continued operational excellence by our team, with the Phase 2 CIPheR trial of MZE782 in PKU now underway with initial topline data expected in…
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data e...
Maze Therapeutics Earnings release: Q2 2026
Maze Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Maze Therapeutics Quarterly report: Q2 2026
Maze Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Maze Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
MZE829 showed robust efficacy and safety in phase II for APOL1 kidney disease, with pivotal studies planned for 2027 and full data expected by 2026/2027. MZE782 demonstrated best-in-class potential for PKU, with phase II data due in 2027. Cash runway extends through 2029.
Maze Therapeutics Transcript: AGM 2026
The meeting featured the election of two directors and ratification of the auditor, both approved by majority vote. No shareholder questions were submitted, and final results will be filed with the SEC.
Maze Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The presentation highlighted progress in developing small molecule therapies for renal and metabolic diseases, with lead programs MZE829 and MZE782 advancing through clinical trials. Strong financials support a runway into 2029, enabling multiple data catalysts and pivotal studies in APOL1 kidney disease and PKU.
Maze Therapeutics Slides: Investor presentation
Maze Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.